TY - JOUR
T1 - Tumor evolution
T2 - Linear, branching, neutral or punctuated?
AU - Davis, Alexander
AU - Gao, Ruli
AU - Navin, Nicholas
N1 - Funding Information:
This study was supported by a grant from the Lefkofsky Family Foundation. This work is also supported by a grant to N.N. from NCI (1RO1CA169244-01) and from the American Cancer Society (129098-RSG-16-092-01-TBG). N.N. is a T.C. Hsu Endowed Scholar, AAAS Wachtel Scholar and Andrew Sabin Family Fellow. The study is also supported by the Moonshot Knowledge Gap Award. A.D. was supported by a fellowship from the American Legion Auxiliary (ALA) foundation. We thank Alexandria Plumer for reviewing the manuscript.
Publisher Copyright:
© 2017 Elsevier B.V.
PY - 2017/4
Y1 - 2017/4
N2 - Intratumor heterogeneity has been widely reported in human cancers, but our knowledge of how this genetic diversity emerges over time remains limited. A central challenge in studying tumor evolution is the difficulty in collecting longitudinal samples from cancer patients. Consequently, most studies have inferred tumor evolution from single time-point samples, providing very indirect information. These data have led to several competing models of tumor evolution: linear, branching, neutral and punctuated. Each model makes different assumptions regarding the timing of mutations and selection of clones, and therefore has different implications for the diagnosis and therapeutic treatment of cancer patients. Furthermore, emerging evidence suggests that models may change during tumor progression or operate concurrently for different classes of mutations. Finally, we discuss data that supports the theory that most human tumors evolve from a single cell in the normal tissue. This article is part of a Special Issue entitled: Evolutionary principles - heterogeneity in cancer?, edited by Dr. Robert A. Gatenby.
AB - Intratumor heterogeneity has been widely reported in human cancers, but our knowledge of how this genetic diversity emerges over time remains limited. A central challenge in studying tumor evolution is the difficulty in collecting longitudinal samples from cancer patients. Consequently, most studies have inferred tumor evolution from single time-point samples, providing very indirect information. These data have led to several competing models of tumor evolution: linear, branching, neutral and punctuated. Each model makes different assumptions regarding the timing of mutations and selection of clones, and therefore has different implications for the diagnosis and therapeutic treatment of cancer patients. Furthermore, emerging evidence suggests that models may change during tumor progression or operate concurrently for different classes of mutations. Finally, we discuss data that supports the theory that most human tumors evolve from a single cell in the normal tissue. This article is part of a Special Issue entitled: Evolutionary principles - heterogeneity in cancer?, edited by Dr. Robert A. Gatenby.
KW - Cancer biology
KW - Cancer genomics
KW - Genome evolution
KW - Intratumor heterogeneity
KW - Single cell genomics
KW - Tumor evolution
UR - http://www.scopus.com/inward/record.url?scp=85011390859&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85011390859&partnerID=8YFLogxK
U2 - 10.1016/j.bbcan.2017.01.003
DO - 10.1016/j.bbcan.2017.01.003
M3 - Article
C2 - 28110020
AN - SCOPUS:85011390859
SN - 0304-419X
VL - 1867
SP - 151
EP - 161
JO - Biochimica et Biophysica Acta - Reviews on Cancer
JF - Biochimica et Biophysica Acta - Reviews on Cancer
IS - 2
ER -
